Greece situation worsens as Novo Nordisk and Leo Pharma hit out on product supplies
This article was originally published in Scrip
Executive Summary
Two Danish firms have reacted strongly to Greece's 29 April market decree – which would see price cuts of 25% on average – with Leo Pharma saying it will withdraw a significant number of products off the market and Novo Nordisk refusing to sell the bulk of its products at the new prices.